Prediction of treatment failure in patients with glioblastoma with perfusion MRI and molecular biomarkers
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 06.05.2026. Verfasst von Riccardo Ludovichetti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Basel Research Fund for Excellent Junior Researchers.
Abstract (Originalsprache)
Background
Predicting early treatment failure in glioblastoma remains challenging. Given the median survival of 13.5 months, better prognostic biomarkers are needed. This study aimed to identify predictors of early treatment failure and their association with overall survival (OS).
Methods
We performed a retrospective analysis of consecutive patients with newly diagnosed glioblastoma who underwent DSC- and DCE-MRI before surgery and radiochemotherapy. Treatment failure was defined as tumor progression per RANO 2.0 criteria within 6 months of surgery. Factors independently associated with outcome among clinical, MRI perfusion at the diagnosis and molecular parameters were identified using multivariable logistic regression models. OS was evaluated using a 180-day landmark analysis to avoid time-dependent bias.
Results
Among 62 patients diagnosed between 01/2017 and 12/2021, 44 patients (71%) were non-responders and 18 patients (29%) responders. Elevated pretreatment rCBV and Ktrans were associated with treatment response (P < .05), with non-responders showing lower median rCBV (4.15 vs 5.90) and Ktrans (0.15 vs 0.17 min−1). A model, including age, perfusion metrics, and MGMT methylation status showed robust discrimination (AUC = 0.84, 95% CI: [0.73; 0.95]) to identify non-responders. Landmark analysis showed no evidence for early treatment failure itself to be associated with OS (P = .40), whereas MGMT promoter methylation status was associated with long-term survival and reduced hazard of death (HR: 0.31, 95% CI: 0.17-0.55; P < .001).
Conclusion
Pretreatment MRI perfusion metrics may predict short-term treatment failure and may guide early experimental therapy, while the MGMT status remains the primary determinant of long-term survival.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroradiology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
- Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
- Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
- Department of Neurorehabilitation, Clinic Lengg, Zurich, Switzerland (E.L.R.).
- Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
- University of Basel, Basel, Switzerland.
ORCID-Profile: Gergely Bertalan, Nicolin Hainc, Andrea Bink, Emilie Le Rhun, Ulrike Held, Michael Weller, Zsolt Kulcsar, Ramona-Alexandra Todea
Förderung
- University of Basel Research Fund for Excellent Junior Researchers
Zitieren
APA
Ludovichetti, R., Villiers, J., Bertalan, G., Hainc, N., Bink, A., Le Rhun, E., Held, U., Weller, M., Kulcsar, Z., & Todea, R. A. (2026). Prediction of treatment failure in patients with glioblastoma with perfusion MRI and molecular biomarkers. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag119
Vancouver
Ludovichetti R, Villiers J, Bertalan G, Hainc N, Bink A, Le Rhun E, et al. Prediction of treatment failure in patients with glioblastoma with perfusion MRI and molecular biomarkers. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag119
BibTeX
@article{Ludovichetti2026,
author = {Ludovichetti, Riccardo and Villiers, Jordan and Bertalan, Gergely and Hainc, Nicolin and Bink, Andrea and Le Rhun, Emilie and Held, Ulrike and Weller, Michael and Kulcsar, Zsolt and Todea, Ramona-Alexandra},
title = {Prediction of treatment failure in patients with glioblastoma with perfusion MRI and molecular biomarkers},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag119}
}
EUVIMED